X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.


Latest Post

May 01, 2020

Injectable Combination Product Development: Facilitating Risk-Based Assessments for Efficiency and Patient Centric Outcomes

The environment for developing an injectable drug device combination product (CP) is dynamic from a regulatory and technical perspective. At the center of it all are the patients and their needs. West is pleased to announce the publication of its review manuscript that provides a detailed overview of best practices for this kind of development program. It considers technical and regulatory aspects and can be used as a foundational document for drug formulators, scientists and engineers working in this area.
Fran DeGrazio

Fran DeGrazio

Chief Scientific Officer, Strategy & Science Integration

Previous Posts
SmartDose Platform

April 26, 2019

Overcoming Challenges Associated with Biologic Drug Formulation and Development

Victoria Morgan

Victoria Morgan

Director, Segment Marketing, Global Biologics

Introducing Integrated Solutions

October 08, 2018

Introducing Integrated Solutions

Deirdre Swinden

Deirdre Swinden

Director, Marketing Communications

The SmartDose Platform in use

August 10, 2018

Combination Products - Why Design Verification Studies Are Needed

Daniel Bantz

Daniel Bantz

Technical Manager, Packaging & Performance, Lab

Load more